Walvax Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), in cooperation with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co. (hereinafter referred to as the "RQ3033 Vaccine" or the "Vaccine") developed by the Company in cooperation with Fudan University and Shanghai Blue Magpie Bio-pharmaceutical Company Limited (hereinafter referred to as the "Shanghai Blue Magpie"), which was approved by the relevant state departments for inclusion in the Emergency Use Program after receiving a letter from the Vaccine Research and Development Task Force of the State Council's Research and Development Group of the Joint Prevention and Joint Control Mechanism on December 1, 2023 The "Vaccine" was approved for emergency use by the relevant state departments.

The RQ3033 vaccine is an iterative vaccine developed on the basis of the mRNA technology platform jointly established by the Company, Fudan University and Shanghai Blue Magpie, and on the basis of the first-generation vaccine, i.e., the mRNA vaccine of the new coronavirus variant (S protein chimerism) (hereinafter referred to as the "RQ3013 vaccine"). This vaccine is a monovalent vaccine designed to target the current neocoronavirus OmicronXBB and meets the latest World Health Organization recommendation to prioritize the use of monovalent neocoronavirus vaccines containing the OmicronXBB antigenic component.

The RQ3033 vaccine is indicated for use in persons 18 years of age and older for the prevention of disease caused by the current predominantly endemic strain of neocoronavirus, Omicron XBB, EG.5 (COVID-19).

https://www.walvax.com/investor_ship/